Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CC-220 (Iberdomide) in Systemic Lupus Erythematosus
NCT02185040Phase 2Completed
- Sponsor
- Celgene Corporation
- Start
- Sep 2014
- Primary completion
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of iberdomide in systemic lupus erythematosus (SLE), sponsored by Celgene Corporation. Started Sep 2014; status: completed.
02
Drugs
iberdomide
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT02185040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02185040.